Although @entity1 with @entity191 ( @entity191 ) experience pelvic organ dysfunction of the urinary bladder, bowel and genital organs, an accurate incidence of the dysfunction and its characteristics have yet to be ascertained. We devised a detailed questionnaire on these three pelvic organ functions in @entity191 @entity1 and control subjects, in our search for a hallmark that would distinguish between the two groups. The @entity191 group comprised 115 @entity1 ; 52 @entity1 and 63 @entity1 , age range 35-69 (average 59) years old, average duration of illness 6 years, median Hoehn and Yahr stage 3. All were taking levodopa with/without @entity935 agonists. The control group comprised 391 local individuals who were undergoing an annual health survey; 271 @entity1 and 120 @entity1 , age range 30-69 (average 48) years old. The questionnaire had three parts: bladder (nine questions), bowel (four questions), and sexual (three questions for @entity1 , five for @entity1 ) function. Each question was scored from 0 (none) to 3 (severe) with an additional quality of life (QOL) index scored from 0 (satisfied) to 3 (extremely dissatisfied). The completion rate was 100% for bladder and bowel functions, whereas for sexual function, it was 95% (control) and 88% ( @entity191 ) for @entity1 and 82% (control) and 60% ( @entity191 ) for @entity1 . As compared with the control group, the frequency of dysfunction in the @entity191 group was significantly higher for urinary urgency ( @entity1 42%, @entity1 54%), daytime frequency (28%, 16%), nighttime frequency (53%, 63%), urgency @entity322 (25%, 28%), retardation (44% of @entity1 ), prolongation/poor stream ( @entity1 70%), straining ( @entity1 28%); @entity1142 (63%, 69%), difficulty in expulsion ( @entity1 57%), @entity294 ( @entity1 21%); decrease in libido (84%, 83%), decrease in sexual intercourse (55%, 88%), decrease in orgasm ( @entity1 87%), and in @entity1 , decreases in erection (79%) and ejaculation (79%). The QOL index for the @entity191 @entity1 was significantly higher for bladder (27%, 28%) and bowel (46%, 59%) but not for @entity250 , despite the group's high prevalence of @entity250 . In the @entity191 @entity1 , fecal @entity322 was associated with @entity322 . Stress @entity322 and a decrease in libido were more common in @entity1 than in @entity1 . @entity1494 , but not @entity250 increased with the Hoehn and Yahr stage. @entity250 , but neither @entity1494 , increased with age. @entity1 taking levodopa and @entity2847 more frequently had bladder (voiding phase) dysfunction than those taking levodopa only. The findings show that bladder, bowel and @entity250 are all prominent in @entity1 with @entity191 . @entity881 , particularly @entity29 which most affects the quality of life, therefore should be a primary target in the treatment of @entity1 with @entity191 .

Questionnaire-based assessment of pelvic organ dysfunction in XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men'] @entity2847 :: ('MESH:D001971', 'Chemical') :: ['bromocriptine'] @entity322 :: ('MESH:D014549', 'Disease') :: ['urinary incontinence', 'incontinence'] @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder nor bowel dysfunction', 'Bladder and bowel dysfunction'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity29 :: ('MESH:D015212', 'Disease') :: ['bowel dysfunction'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", 'PD'] @entity881 :: ('MESH:D009102', 'Disease') :: ['Amelioration of pelvic organ dysfunction'] @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation'] @entity250 :: ('MESH:D012735', 'Disease') :: ['sexual dysfunction', 'Sexual dysfunction']
@entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']
